therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2025-6-4-124-131therapeutic-660Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESОстрый инфаркт миокарда у пациентки молодого возраста с жировой болезнью печени, ассоциированной с метаболической дисфункцией (MAFLD)Acute myocardial infarction in a young female patient with fatty liver disease associated with metabolic dysfunction (MAFLD)https://orcid.org/0000-0002-8653-7727НосковаЕ. В.NoskovaE. V.

Носкова Елена Владимировна, к.м.н., ассистент кафедры госпитальной терапии ФГБОУ ВО «Кировский Государственный медицинский университет» Минздрава России; Киров, Россия; врач-кардиолог отделения неотложной кардиологии КОГБУЗ «Кировская областная клиническая больница»

Киров

Elena V. Noskova, Cand. Sci. (Med.), assistant Professor of Hospital Therapy, Kirov State Medical University; cardiologist at the Department of Emergency Cardiology, Kirov Regional Clinical Hospital

Kirov

noslena2016@yandex.ruhttps://orcid.org/0000-0002-9772-3867СимоноваЖ. Г.SimonovaZh. G.

Симонова Жанна Георгиевна, д.м.н., профессор, профессор, заведующий кафедрой госпитальной терапии 

Киров

Zhanna G. Simonova, Dr. Sci. (Med.), Professor, Professor, Head of the Department of Hospital Therapy 

Kirov

simonova-kirov@rambler.ruФГБОУ ВО «Кировский государственный медицинский университет» Минздрава России; КОГБУЗ «Кировская областная клиническая больница»РоссияKirov State Medical University; Kirov Regional Clinical HospitalRussian FederationФГБОУ ВО «Кировский государственный медицинский университет» Минздрава РоссииРоссияKirov State Medical UniversityRussian Federation20252312202564124131Copyright © Носкова Е.В., Симонова Ж.Г., 20252025Носкова Е.В., Симонова Ж.Г.Noskova E.V., Simonova Z.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/660

Разбор данного клинического случая направлен на понимание вклада метаболических заболеваний в развитие и дальнейшее течение острого инфаркта миокарда. В наши дни доказано, что неалкогольная жировая болезнь печени (НАЖБП) и метаболический синдром (МС) тесно связаны с сердечно-сосудистыми заболеваниями, особенно с ишемической болезнью сердца (ИБС). Стеатоз печени, ассоциированный с метаболической дисфункцией, представляет собой растущую проблему для здоровья населения. Метаболическая дисфункция и связанная с ней инсулинорезистентность, сопряжены с повышенным риском развития эндотелиальной дисфункции и системного воспалительного ответа. Эта сложная патофизиология ускоряет атерогенную дислипидемию, атерогенез, диастолическую дисфункцию и сердечные аритмии. Углубленное изучение проблематики единых патогенетических механизмов у коморбидных пациентов позволит своевременно предотвратить развитие острых событий в течение хронических неинфекционных заболеваний.

The analysis of this clinical case is aimed at understanding the contribution of metabolic diseases to the development and further course of acute myocardial infarction. Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) have been proven to be closely linked to cardiovascular disease, especially coronary heart disease. Hepatic steatosis associated with metabolic dysfunction is a growing public health problem. Metabolic dysfunction and associated insulin resistance are associated with an increased risk of endothelial dysfunction and systemic inflammatory response. This complex pathophysiology accelerates atherogenic dyslipidemia, atherogenesis, diastolic dysfunction, and cardiac arrhythmias. An in-depth study of the problems of unified pathogenetic mechanisms in comorbid patients will allow timely prevention of the development of acute events in the course of chronic non-communicable diseases.

острый инфаркт миокардаметаболический синдромстеатоз печениacute myocardial infarctionmetabolic syndromehepatic steatosisReferencesArora S, Stouffer GA, Kucharska-Newton AM, Qamar A, Vaduganathan M, Pandey A, et al. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation. 2019;139(8):1047-1056. doi: 10.1161/CIRCULATIONAHA.118.037137Arora S, Stouffer GA, Kucharska-Newton AM, Qamar A, Vaduganathan M, Pandey A, et al. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation. 2019;139(8):1047-1056. doi: 10.1161/CIRCULATIONAHA.118.037137Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-319-48382-5_1Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-319-48382-5_1Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract. 2022;188:109924. doi: 10.1016/j.diabres.2022.109924Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract. 2022;188:109924. doi: 10.1016/j.diabres.2022.109924Шварц В. Воспаление жировой ткани. Часть 3. Патогенетическая роль в развитии атеросклероза. Проблемы Эндокринологии. 2009;55(6):40-45. doi: 10.14341/probl200955640-45Shvarts V. Inflammation of adipose tissue. Part 3. Pathogenetic role in the development of atherosclerosis. Problems of Endocrinology. 2009;55(6):40-45. (In Russ.) doi: 10.14341/probl200955640-45Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: A review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891. doi: 10.1016/j.diabres.2024.111891Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: A review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891. doi: 10.1016/j.diabres.2024.111891Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270. doi: 10.1186/s12933-022-01697-0Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270. doi: 10.1186/s12933-022-01697-0Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28-34. doi: 10.1016/j.ejim.2023.11.012Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28-34. doi: 10.1016/j.ejim.2023.11.012Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59 Suppl 1:S10-S22. doi: 10.1111/apt.17930Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59 Suppl 1:S10-S22. doi: 10.1111/apt.17930Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039Liu HH, Cao YX, Jin JL, Hua Q, Li YF, Guo YL, et al. Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. J Am Heart Assoc. 2021;10(3):e018869. doi: 10.1161/JAHA.120.018869Liu HH, Cao YX, Jin JL, Hua Q, Li YF, Guo YL, et al. Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. J Am Heart Assoc. 2021;10(3):e018869. doi: 10.1161/JAHA.120.018869Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, et al. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res. 2021;198:139-150. doi: 10.1016/j.thromres.2020.12.002Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, et al. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res. 2021;198:139-150. doi: 10.1016/j.thromres.2020.12.002Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050Pacana T, Cazanave S, Verdianelli A, Patel V, Min HK, Mirshahi F, et al. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One. 2015;10(8):e0136822. doi: 10.1371/journal.pone.0136822Pacana T, Cazanave S, Verdianelli A, Patel V, Min HK, Mirshahi F, et al. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One. 2015;10(8):e0136822. doi: 10.1371/journal.pone.0136822Hörber S, Lehmann R, Stefan N, Machann J, Birkenfeld AL, Wagner R, et al. Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Mol Metab. 2021;53:101262. doi: 10.1016/j.molmet.2021.101262Hörber S, Lehmann R, Stefan N, Machann J, Birkenfeld AL, Wagner R, et al. Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Mol Metab. 2021;53:101262. doi: 10.1016/j.molmet.2021.101262Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121-129. doi: 10.1002/hep.26510Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121-129. doi: 10.1002/hep.26510Alshammary AF, Alharbi KK, Alshehri NJ, Vennu V, Ali Khan I. Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2021;18(4):1773. doi: 10.3390/ijerph18041773Alshammary AF, Alharbi KK, Alshehri NJ, Vennu V, Ali Khan I. Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2021;18(4):1773. doi: 10.3390/ijerph18041773Montazerifar F, Bolouri A, Mahmoudi Mozaffar M, Karajibani M. The Prevalence of Metabolic Syndrome in Coronary Artery Disease Patients. Cardiol Res. 2016;7(6):202-208. doi: 10.14740/cr507wMontazerifar F, Bolouri A, Mahmoudi Mozaffar M, Karajibani M. The Prevalence of Metabolic Syndrome in Coronary Artery Disease Patients. Cardiol Res. 2016;7(6):202-208. doi: 10.14740/cr507wChan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32(3):197-213. doi: 10.7570/jomes23052Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32(3):197-213. doi: 10.7570/jomes23052Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, et al. Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022;117(3):453-461. doi: 10.14309/ajg.0000000000001606Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, et al. Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022;117(3):453-461. doi: 10.14309/ajg.0000000000001606Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018;270:245-252. doi: 10.1016/j.ijcard.2018.05.087Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018;270:245-252. doi: 10.1016/j.ijcard.2018.05.087Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31(2):176-183. doi: 10.1111/j.1478-3231.2010.02375.xKotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31(2):176-183. doi: 10.1111/j.1478-3231.2010.02375.xНоскова Е.В., Симонова Ж.Г., Баландина Ю.А. Фенотип бронхиальной астмы с ожирением в сочетании с хронической ишемической болезнью сердца. Южно-Российский журнал терапевтической практики. 2023;4(2):64-72. doi: 10.21886/2712-8156-2023-4-2-64-72Noskova E.V., Simonova Zh.G., Balandina Yu.A. Phenotype of bronchial asthma with obesity in combination with chronic coronary heart disease. South Russian Journal of Therapeutic Practice. 2023;4(2):64-72. (In Russ.) doi: 10.21886/2712-8156-2023-4-2-64-72

The authors declare that there are no conflicts of interest present.